Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

4

Portfolio Exits

1

About Tong Chen

Tong Chen is the president of Yidian Zixun.

Tong Chen Headquarter Location

Beijing, Beijing,

China

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Tong Chen News

The Product of Red Blood Cells and Hematocrit Can Be Used as a Novel Indicator of Impaired Fasting Blood Glucose Status

Oct 26, 2020

Ling Feng,* Haishan Chen,* Jianhui Chen, Chongxiang Xiong, Xiaofei Shao, Xin Wang, Jing Ning, Zhicong Xiang, Xuan Wang, Tong Chen, Hua Xiao, Hongjuan Tang, Xiaolin Li, Guobao Hong, Hequn Zou Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, Guangzhou 510630, People’s Republic of China *These authors contributed equally to this work. Correspondence: Hequn Zou; Xiaofei Shao Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, 183, Zhongshan West Avenue, Tianhe District, Guangzhou 510630, People’s Republic of China Email Hequnzou@hotmail.com; 413151187@qq.com Objective: To explore whether the red blood cell count multiplied by hematocrit index (RBCHct) in blood routine parameters can indicate the risk of impaired fasting blood glucose (IFG), and whether it is related to insulin resistance and inflammation. Methods: In this cross-sectional study, previous history of diabetes was excluded, and people with normal and impaired IFG were included. We use Spearman analysis to evaluate the correlation between RBCHct index and fasting plasma glucose, insulin resistance homeostasis model assessment (HOMA-IR), and hypersensitive C-reactive protein (hs-CRP). Binary logistic regression analysis was used to evaluate the RBCHct index for assessing the potential risk of IFG, and the receiver operating characteristic (ROC) curve was used to evaluate the RBCHct index for diagnosing insulin resistance and chronic low-grade inflammatory efficacy among those with IFG. Results: Correlation analysis showed that the RBCHct index and fasting plasma glucose (r=0.088, P=0.003); HOMA-IR (r=0.199, P< 0.001); and hs-CRP (r=0.097, P=0.001) were positively correlated. After adjusting for confounding factors, the risk of IFG in the third and fourth quartiles of the RBCHct index increased to 1.889 and 3.048 times. The area under the ROC curve of the RBCHct index for diagnosis of insulin resistance state (HOMA-IR) was 0.695 (p< 0.001), and the area under the ROC curve of the RBCHct index for the diagnosis of chronic low-inflammatory state (hs-CRP) was 0.641 (P=0.010). Conclusion: The RBCHct index may be a potential indicator for assessing the risk of prediabetes and is closely related to whether the body is in a state of insulin resistance and inflammation under IFG. Keywords: diabetes mellitus, erythrocyte, RBCHct index, insulin resistance, inflammation This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License . By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms .

Tong Chen Investments

4 Investments

Tong Chen has made 4 investments. Their latest investment was in STEPVR as part of their Series B on May 5, 2021.

CBI Logo

Tong Chen Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/12/2021

Series B

STEPVR

$15.66M

No

1

1/1/2021

Series A - III

Subscribe to see more

$99M

Subscribe to see more

10

3/1/2017

Series A

Subscribe to see more

$99M

Subscribe to see more

10

1/13/2016

Angel

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/12/2021

1/1/2021

3/1/2017

1/13/2016

Round

Series B

Series A - III

Series A

Angel

Company

STEPVR

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$15.66M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

Tong Chen Portfolio Exits

1 Portfolio Exit

Tong Chen has 1 portfolio exit. Their latest portfolio exit was JiyangWenhua Media on December 11, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/11/2019

IPO

2

Date

12/11/2019

Exit

IPO

Companies

Valuation

Acquirer

Sources

2

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.